Suppr超能文献

黏多糖贮积症 I 型患者的诊断历程:患者及医生经历的真实世界调查

The diagnostic journey of patients with mucopolysaccharidosis I: A real-world survey of patient and physician experiences.

作者信息

Bruni Stefano, Lavery Christine, Broomfield Alexander

机构信息

Sanofi Genzyme, Strada Scaglia Est 136, 41126 Modena, Italy.

Society for Mucopolysaccharide Diseases, MPS House, Repton Place, White Lion Road, Amersham, Buckinghamshire HP7 9LP, UK.

出版信息

Mol Genet Metab Rep. 2016 Aug 2;8:67-73. doi: 10.1016/j.ymgmr.2016.07.006. eCollection 2016 Sep.

Abstract

UNLABELLED

Mucopolysaccharidosis type I (MPS I) is an inherited lysosomal storage disease. Affected individuals have disease ranging from attenuated to severe with significant disease burden, disability, and premature death. Early treatment with enzyme replacement therapy and/or stem cell transplantation can reduce disease progression and improve outcomes. However, diagnosis is often delayed, particularly for patients with attenuated phenotypes. We conducted a survey of 168 patients and 582 physicians to explore health care seeking patterns and familiarity of physicians with MPS I symptoms. Patients with attenuated MPS I typically first presented with stiff joints or hernia/bulging abdomen, and patients with severe disease with noisy/difficult breathing, or hernia/bulging abdomen. There was a mean delay from time of symptom presentation to diagnosis of 2.7 years for patients with attenuated disease, with a mean of 5 physicians consulted before receiving a correct diagnosis. MPS I was most commonly misidentified by physicians as rheumatoid arthritis (48-72%), with a wide variety of suspected diseases, including lupus.

CONCLUSION

Patient and physician real-world surveys show that MPS I is under-recognized and diagnosis of MPS I remains delayed, particularly in patients with attenuated disease. Across regions and specialties, physicians require differential diagnosis education in order to improve early detection and early treatment initiation of MPS I.

摘要

未标注

I型黏多糖贮积症(MPS I)是一种遗传性溶酶体贮积病。受影响的个体病情从轻度到重度不等,疾病负担、残疾和过早死亡情况严重。早期采用酶替代疗法和/或干细胞移植治疗可减缓疾病进展并改善预后。然而,诊断往往延迟,尤其是对于症状较轻的患者。我们对168名患者和582名医生进行了一项调查,以探究就医模式以及医生对MPS I症状的熟悉程度。症状较轻的MPS I患者通常最初表现为关节僵硬或疝气/腹部隆起,而重症患者则表现为呼吸嘈杂/困难或疝气/腹部隆起。症状较轻的患者从出现症状到确诊的平均延迟时间为2.7年,在得到正确诊断之前平均咨询了5名医生。MPS I最常被医生误诊为类风湿性关节炎(48 - 72%),还存在多种疑似疾病,包括狼疮。

结论

患者和医生的实际情况调查表明,MPS I未得到充分认识,MPS I的诊断仍然延迟,尤其是在症状较轻的患者中。在各个地区和专业领域,医生都需要接受鉴别诊断教育,以改善MPS I的早期检测和早期治疗启动情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93d0/4975775/addf524f50d0/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验